Imugene Limited (ASX:IMU) non-executive director Charles Walker has made an indirect purchase of 172,500 shares in the company.
The purchase for 16.5 cents per share by a director related entity brings Walker’s total securities to 28,523,210 (direct and indirect holdings).
Managing director and chief executive officer Leslie Chong also made two seperate share purchases; 400,000 shares at 2.2 cents per share and 475,240 at 1.8 cents per share.
She now holds 4,387,124 shares and 77,098,765 options in the company.
Immuno-oncology treatments
Imugene is focused on developing immuno-oncology treatments CF33 and PD1-Vaxx in first-in-human studies.
CF33 has been shown to efficiently shrink injected tumours and distant non-injected tumours in human triple-negative breast cancer, colon cancer, ovarian cancer xenograft models in mice without adverse effects.
The company’s PD1-Vaxx is a B-cell immunotherapy, peptide cancer vaccine designed to treat tumours such as lung cancer and will be trialled on patients in 2020.
The company is continuing enrolment of its HER-Vaxx phase-2 study, which is a therapeutic cancer vaccine for the treatment of gastric cancer and breast cancer with Phase 2 studies underway.